|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Claritin-D
|
|
gptkbp:approves
|
gptkb:2000
gptkb:FDA
|
|
gptkbp:average_temperature
|
room temperature
|
|
gptkbp:body_style
|
oval
|
|
gptkbp:class
|
gptkb:drug
decongestant
|
|
gptkbp:clinical_trial
|
gptkb:battle
|
|
gptkbp:color
|
gptkb:blue
|
|
gptkbp:contains
|
gptkb:loratadine
gptkb:pseudoephedrine
|
|
gptkbp:contraindication
|
hypertension
MAO inhibitors
severe coronary artery disease
|
|
gptkbp:dosage_form
|
extended-release tablet
|
|
gptkbp:formulation
|
oral
|
|
gptkbp:has_ability
|
120 mg pseudoephedrine
5 mg loratadine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CLARITIN-D
|
|
gptkbp:imprints
|
gptkb:CLARITIN-D
|
|
gptkbp:ingredients
|
gptkb:loratadine
gptkb:pseudoephedrine
|
|
gptkbp:interacts_with
|
gptkb:beer
other antihistamines
certain antidepressants
|
|
gptkbp:is_available_in
|
various strengths
|
|
gptkbp:is_available_on
|
gptkb:tablet
|
|
gptkbp:is_used_for
|
allergy relief
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:population
|
do not exceed recommended dose
consult doctor if symptoms persist
read the label
take as directed
|
|
gptkbp:previous_name
|
gptkb:battle
loratadine and pseudoephedrine
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:safety_features
|
consult healthcare provider
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
stomach upset
drowsiness
insomnia
dry mouth
nervousness
|
|
gptkbp:suitable_for
|
pregnant women
children under 12
nursing mothers
|
|
gptkbp:symptoms
|
confusion
seizures
none reported
rapid heartbeat
severe dizziness
|